NEXPLANON

This brand name is authorized in United States. It is also authorized in Canada, Estonia, Finland, France, Lithuania, Romania, Turkey, UK.

Active ingredients

The drug NEXPLANON contains one active pharmaceutical ingredient (API):

1	Etonogestrel UNII 304GTH6RNH - ETONOGESTREL
	Etonogestrel is the biologically active metabolite of desogestrel, a progestagen widely used in OCs. It is structurally derived from 19-nortestosterone and binds with high affinity to progesterone receptors in the target organs. The contraceptive effect of etonogestrel is primarily achieved by inhibition of ovulation.
	Read more about Etonogestrel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NEXPLANON Implant	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03AC08	Etonogestrel	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AC Progestogens
Discover more medicines within G03AC08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02499509
EE	Ravimiamet	1589171, 1657560
FI	Lääkealan turvallisuus- ja kehittämiskeskus	097847
FR	Base de données publique des médicaments	66845924
GB	Medicines & Healthcare Products Regulatory Agency	180308, 381558
LT	Valstybinė vaistų kontrolės tarnyba	1066966, 1073720
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68121001, W68121002
TR	İlaç ve Tıbbi Cihaz Kurumu	8683280337299
US	FDA, National Drug Code	0052-4330